Company intelligence / Profile preview
Ampio Pharmaceuticals, Inc.
Delaware, United Statesampiopharma.com ↗
- Ownership
- Public · AMPE
- Employees
- ~6
- Development stage
- Other
01
Overview
The company's lead candidate Ampion failed to meet FDA standards in clinical trials for osteoarthritis of the knee. Their follow-up candidate OA-201 failed in preclinical animal studies in February 2024, showing inability to reduce pain caused by osteoarthritis. The company has been dissolved as of August 16, 2024, following stockholder approval of a Plan of Dissolution.
- Therapeutic areas
- OphthalmologyImmunologyNeurologyRheumatology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $207.9K
- Total revenue
- $0
- Enterprise value
- $-3.6M
Beyond the preview
Go deeper on Ampio Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ampio Pharmaceuticals, Inc..